Abstract

Methamphetamine (METH) is a frequent drug of abuse in U.S. populations and commonly associated with psychosis. This may be a factor in frequent criminal justice referrals and lengthy treatment required by METH users. Persecutory delusions and auditory hallucinations are the most consistent symptoms of METH-associated psychosis (MAP). MAP has largely been studied in Asian populations and risk factors have varied across studies. Duration, frequency and amount of use as well as sexual abuse, family history, other substance use, and co-occurring personality and mood disorders are risk factors for MAP. MAP may be unique with its long duration of psychosis and recurrence without relapse to METH. Seven candidate genes have been identified that may be associated with MAP. Six of these genes are also associated with susceptibility, symptoms, or treatment of schizophrenia and most are linked to glutamatergic neurotransmission. Animal studies of pre-pulse inhibition, attenuation of social interaction, and stereotypy and alterations in locomotion are used to study MAP in rodents. Employing various models, rodent studies have identified neuroanatomical and neurochemical changes associated with METH use. Throughout this review, we identify key gaps in our understanding of MAP and suggest potential directions for future research.

Original languageEnglish (US)
Pages (from-to)113-139
Number of pages27
JournalJournal of Neuroimmune Pharmacology
Volume7
Issue number1
DOIs
StatePublished - Mar 1 2012

Fingerprint

Methamphetamine
Psychotic Disorders
Rodentia
Recurrence
Criminal Law
Delusions
Hallucinations
Personality Disorders
Sex Offenses
Street Drugs
Locomotion
Interpersonal Relations
Mood Disorders
Synaptic Transmission
Population
Genes
Schizophrenia
Referral and Consultation

Keywords

  • Candidate genes
  • Drug addiction
  • Methamphetamine
  • Psychotic symptoms
  • Schizophrenia
  • Substance use disorder

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Methamphetamine-associated psychosis. / Grant, Kathleen M; LeVan, Tricia D; Wells, Sandra M.; Li, Ming; Stoltenberg, Scott F; Gendelman, Howard Eliot; Carlo, Gustavo; Bevins, Rick A.

In: Journal of Neuroimmune Pharmacology, Vol. 7, No. 1, 01.03.2012, p. 113-139.

Research output: Contribution to journalReview article

@article{c95923215bf44f2ca9c2de3b91050af5,
title = "Methamphetamine-associated psychosis",
abstract = "Methamphetamine (METH) is a frequent drug of abuse in U.S. populations and commonly associated with psychosis. This may be a factor in frequent criminal justice referrals and lengthy treatment required by METH users. Persecutory delusions and auditory hallucinations are the most consistent symptoms of METH-associated psychosis (MAP). MAP has largely been studied in Asian populations and risk factors have varied across studies. Duration, frequency and amount of use as well as sexual abuse, family history, other substance use, and co-occurring personality and mood disorders are risk factors for MAP. MAP may be unique with its long duration of psychosis and recurrence without relapse to METH. Seven candidate genes have been identified that may be associated with MAP. Six of these genes are also associated with susceptibility, symptoms, or treatment of schizophrenia and most are linked to glutamatergic neurotransmission. Animal studies of pre-pulse inhibition, attenuation of social interaction, and stereotypy and alterations in locomotion are used to study MAP in rodents. Employing various models, rodent studies have identified neuroanatomical and neurochemical changes associated with METH use. Throughout this review, we identify key gaps in our understanding of MAP and suggest potential directions for future research.",
keywords = "Candidate genes, Drug addiction, Methamphetamine, Psychotic symptoms, Schizophrenia, Substance use disorder",
author = "Grant, {Kathleen M} and LeVan, {Tricia D} and Wells, {Sandra M.} and Ming Li and Stoltenberg, {Scott F} and Gendelman, {Howard Eliot} and Gustavo Carlo and Bevins, {Rick A}",
year = "2012",
month = "3",
day = "1",
doi = "10.1007/s11481-011-9288-1",
language = "English (US)",
volume = "7",
pages = "113--139",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Methamphetamine-associated psychosis

AU - Grant, Kathleen M

AU - LeVan, Tricia D

AU - Wells, Sandra M.

AU - Li, Ming

AU - Stoltenberg, Scott F

AU - Gendelman, Howard Eliot

AU - Carlo, Gustavo

AU - Bevins, Rick A

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Methamphetamine (METH) is a frequent drug of abuse in U.S. populations and commonly associated with psychosis. This may be a factor in frequent criminal justice referrals and lengthy treatment required by METH users. Persecutory delusions and auditory hallucinations are the most consistent symptoms of METH-associated psychosis (MAP). MAP has largely been studied in Asian populations and risk factors have varied across studies. Duration, frequency and amount of use as well as sexual abuse, family history, other substance use, and co-occurring personality and mood disorders are risk factors for MAP. MAP may be unique with its long duration of psychosis and recurrence without relapse to METH. Seven candidate genes have been identified that may be associated with MAP. Six of these genes are also associated with susceptibility, symptoms, or treatment of schizophrenia and most are linked to glutamatergic neurotransmission. Animal studies of pre-pulse inhibition, attenuation of social interaction, and stereotypy and alterations in locomotion are used to study MAP in rodents. Employing various models, rodent studies have identified neuroanatomical and neurochemical changes associated with METH use. Throughout this review, we identify key gaps in our understanding of MAP and suggest potential directions for future research.

AB - Methamphetamine (METH) is a frequent drug of abuse in U.S. populations and commonly associated with psychosis. This may be a factor in frequent criminal justice referrals and lengthy treatment required by METH users. Persecutory delusions and auditory hallucinations are the most consistent symptoms of METH-associated psychosis (MAP). MAP has largely been studied in Asian populations and risk factors have varied across studies. Duration, frequency and amount of use as well as sexual abuse, family history, other substance use, and co-occurring personality and mood disorders are risk factors for MAP. MAP may be unique with its long duration of psychosis and recurrence without relapse to METH. Seven candidate genes have been identified that may be associated with MAP. Six of these genes are also associated with susceptibility, symptoms, or treatment of schizophrenia and most are linked to glutamatergic neurotransmission. Animal studies of pre-pulse inhibition, attenuation of social interaction, and stereotypy and alterations in locomotion are used to study MAP in rodents. Employing various models, rodent studies have identified neuroanatomical and neurochemical changes associated with METH use. Throughout this review, we identify key gaps in our understanding of MAP and suggest potential directions for future research.

KW - Candidate genes

KW - Drug addiction

KW - Methamphetamine

KW - Psychotic symptoms

KW - Schizophrenia

KW - Substance use disorder

UR - http://www.scopus.com/inward/record.url?scp=84860717734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860717734&partnerID=8YFLogxK

U2 - 10.1007/s11481-011-9288-1

DO - 10.1007/s11481-011-9288-1

M3 - Review article

C2 - 21728034

AN - SCOPUS:84860717734

VL - 7

SP - 113

EP - 139

JO - Journal of NeuroImmune Pharmacology

JF - Journal of NeuroImmune Pharmacology

SN - 1557-1890

IS - 1

ER -